|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.415 HKD | 0.00% |
|
-2.35% | -9.78% |
| Mar. 26 | Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Jan. 10 | Livzon Pharma Recognizes Credit, Asset Impairments | MT |
Mabpharm Limited reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was CNY 87.16 million compared to CNY 55.92 million a year ago. Net loss was CNY 209.36 million compared to CNY 210.82 million a year ago.
Basic loss per share from continuing operations was CNY 0.05 compared to CNY 0.05 a year ago. Diluted loss per share from continuing operations was CNY 0.05 compared to CNY 0.05 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -9.78% | 219M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
MABPHARM LIMITED 
